Key result
Integrated multi-channel assay assessment refines drug-induced TdP liability beyond standard potency ratios alone.
Why the study?
Does integrated assessment of balanced ion-channel block (IKr, ICaL, and INaL) using in vitro, in silico, and hiPSC-CM models improve proarrhythmic torsade de pointes risk evaluation compared to IKr block and QT prolongation alone?
Does integrated assessment of balanced ion-channel block (IKr, ICaL, and INaL) using in vitro, in silico, and hiPSC-CM models improve proarrhythmic torsade de pointes risk evaluation compared to IKr block and QT prolongation alone?
Answers are grounded in this paper and cite their sources.
Assessing balanced block across hERG/Kv11.1, CaV1.2, and NaV1.5 requires integrating in vitro, in silico, and hiPSC-CM evidence rather than relying on simple potency ratios, in alignment with ICH E14/S7B Q&As (R1).
Drug-induced torsade de pointes (TdP) risk is commonly assessed by measuring inhibition of the rapid delayed rectifier potassium current (IKr), mediated by Kv11.1/hERG, together with QT-interval prolongation. These endpoints are sensitive but incompletely specific because concomitant inhibition of the L-type calcium current (ICaL) or late sodium current (INaL) can attenuate IKr-block-mediated repolarization delay. This narrative review evaluates balanced ion-channel block using recombinant-cell electrophysiology, in silico models, and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Potency ratios can describe relative channel inhibition but cannot alone establish a validated risk threshold or low clinical TdP liability. Concentration-response slopes, binding kinetics, unbound exposure, active metabolites, trafficking effects, and patient susceptibility also influence outcome. The CiPA-modified O'Hara-Rudy ventricular model and qNet-derived Torsade Metric Score are model-specific integrators rather than direct measurements of clinical repolarization reserve. The fixed-block simulations presented here illustrate interactions between inward and outward currents. hiPSC-CMs provide complementary functional evidence but remain limited by cellular immaturity and assay variability. The ICH E14/S7B Q&As (R1), adopted in August 2026, support integrated assessment and permit qualified alternative assays in defined contexts of use.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) conducted a review in Drug-induced torsade de pointes (TdP). Balanced ion-channel block assessment (hERG/Kv11.1, CaV1.2, and NaV1.5) vs. IKr inhibition and QT-interval prolongation assessment alone was evaluated on Proarrhythmic risk / Drug-induced torsade de pointes (TdP) liability. Integrated assessment of balanced block (IKr, ICaL, INaL) via in vitro, in silico, and hiPSC-CM assays evaluates TdP liability beyond potency ratios alone, aligning with 2026 ICH E14/S7B Q&As (R1).
Synapse has enriched 10 related papers. Consider them for comparative context: